CICC: Maintaining Outperform rating on Genting Hong Kong (01952) with a target price of 41.5 Hong Kong dollars.

According to the Wise Finance APP, CICC issued a research report stating that it maintains its profit forecasts for 2026 and 2027 for Genting Hong Kong (01952). Based on DCF, it gives an outperform rating and a target price of 41.5 Hong Kong dollars, representing a 48.43% upside potential from the current stock price. On June 2, the company announced an exclusive licensing and collaboration agreement with Travere Therapeutics, granting them exclusive development and commercialization rights for EVER001 (civorebrutinib) outside of Greater China and certain Southeast Asian countries.